文献速递妇科

循环肿瘤DNA监测用于上皮性卵巢癌早期复发检测

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2022-09-16

该研究评估循环肿瘤DNA(ctDNA)在上皮性卵巢癌中的预后价值,并与CA-125比较。术前ctDNA阳性率73%(32/44),术后及随访中ctDNA仅见于复发患者,较影像学平均提前10个月,且为复发的强预测因子(HR 17.6),CA-125阳性则无统计学显著预测价值。

要点

  • 术后或随访中ctDNA阳性仅见于复发患者,敏感度和特异度均为100%。
  • ctDNA阳性较影像学发现复发平均提前10个月。
  • 术后单时间点及随访系列ctDNA阳性预测复发HR 17.6(p=0.001;p<0.0001),CA-125阳性无统计学显著预测价值。

核心结论

  • 术后ctDNA存在对无复发生存期缩短具有高度预后价值,ctDNA在识别复发最高风险患者方面优于CA-125,监测ctDNA可能有益于上皮性卵巢癌临床决策。

研究设计与样本

  • 研究纳入I-IV期上皮性卵巢癌患者,队列A为术前样本(N=44,中位随访2.7年),队列B和C分别为术后系列样本(N=12)和监测期间系列样本(N=13),中位随访2年。
  • 血浆样本采用肿瘤信息指导的个性化多重PCR NGS检测分析,ctDNA状态与CA-125水平同临床特征及结局进行关联分析。

主要发现

  • 全队列基因组谱与TCGA中所见一致。
  • 队列A术前样本ctDNA阳性率为73%(32/44),高级别核级疾病中更高。
  • 队列B和C中ctDNA仅见于复发患者,敏感度和特异度均为100%,较影像学发现平均提前10个月。
  • 术后(±辅助化疗)单时间点及监测期间系列ctDNA阳性为复发的强预测因子(HR 17.6,p=0.001和p<0.0001),CA-125阳性则不是(p=0.113和p=0.056)。

关键数值与推荐

  • 队列A术前ctDNA阳性率73%(32/44)。
  • 队列B和C中ctDNA检测复发的敏感度和特异度均为100%,较影像学平均提前10个月。
  • 术后单时间点ctDNA阳性预测复发HR 17.6(p=0.001),监测期间系列ctDNA阳性预测复发HR 17.6(p<0.0001)。
  • CA-125阳性预测复发p=0.113和p=0.056,未达统计学显著。

临床怎么用

  • 作者认为监测ctDNA可能有益于上皮性卵巢癌患者的临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. We examined the utility of circulating tumor DNA (ctDNA) as a prognostic biomarker for EOC by assessing its relationship with patient outcome and CA-125, pre-surgically and during post-treatment surveillance. METHODS: Plasma samples were collected from patients with stage I-IV EOC. Cohort A included patients with pre-surgical samples (N = 44, median follow-up: 2.7 years), cohort B and C included: patients with serially collected post-surgically (N = 12) and, during surveillance (N = 13), respectively (median follow-up: 2 years). Plasma samples were analyzed using a tumor-informed, personalized multiplex-PCR NGS assay; ctDNA status and CA-125 levels were correlated with clinical features and outcomes. RESULTS: Genomic profiling was performed on the entire cohort and was consistent with that seen in TCGA. In cohort A, ctDNA-positivity was observed in 73% (32/44) of presurgical samples and was higher in high nuclear grade disease. In cohort B and C, ctDNA was only detected in patients who relapsed (100% sensitivity and specificity) and preceded radiological findings by an average of 10 months. The presence of ctDNA at a single timepoint after completion of surgery +/- adjuvant chemotherapy and serially during surveillance was a strong predictor of relapse (HR:17.6, p = 0.001 and p < 0.0001, respectively), while CA-125 positivity was not (p = 0.113 and p = 0.056). CONCLUSIONS: The presence of ctDNA post-surgically is highly prognostic of reduced recurrence-free survival. CtDNA outperformed CA-125 in identifying patients at highest risk of recurrence. These results suggest that monitoring ctDNA could be beneficial in clinical decision-making for EOC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hou JY, Chapman JS, Kalashnikova E, et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecol Oncol. 2022. PMID: 36117009. doi:10.1016/j.ygyno.2022.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。